Amarin Corp Plc (AMRN)

[sts66]

Something about that ROW excluding China and EU - that $1B is potential revs from royalties - KM said they will partner in those countries:

We also plan to implement an agency distributorship model in most Central and Eastern European markets. What it does not make business sense for us to have our own Amarin presence.

In many of these markets, we may not choose to be present ourselves and have already received requests for agency distributorship partnerships. Such collaborations have the advantage of giving us control over the marketing authorization of our product, and providing optionality as we grow the business globally. Collectively, this international expansion gives us access to another billion dollar market opportunity for Amarin to leverage, while making a difference in the lives of many millions of patients across the globe.

If you look at Latin America countries like Mexico, Brazil; if you look at Asia countries like Korea are very important countries from a lipid market perspective and a cardiovascular perspective. And in these countries, we believe we do not need to go ourselves to build an infrastructure. We can partner in a different evolved model that will allow us to sort of maintain our marketing authorization, maintain optionality and continue to sort of drive our performance at a global level. So that's the answer on the incremental $1 billion outside of U.S. and Europe.

Discussions on partners are mostly around what we discussed for Central, Eastern Europe, and for partnerships in the rest of the world international markets, and there are more in the agency distributor type model, but we cannot comment further at this stage

Speaking of which, if you look at what they got in royalties from HLS in H1/21, appears royalty rate is 8% - so if that rate is the norm (in the ballpark of norm), you're looking at > $10B of ROW sales to get $1B to AMRN - doesn't sound possible.